Disease · MONDO_0019087
Comparisons in its trials42
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 42
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Cohort 3b: Colorectal Cancer - Vemurafenib + Cetuximab vs Pooled Arm - Vemurafenib: serious adverse events | 11 of 27 | 91 of 181 | 208 | NCT01524978 | Trial comparisons |
| Gemcitabine + Sorafenib vs Gemcitabine + Placebo: serious adverse events | 33 of 49 | 35 of 48 | 97 | NCT00661830 | Trial comparisons |
| Arm A (Atezolizumab) vs Arm B (Atezolizumab, Cobimetinib): deaths from any cause | 35 of 43 | 35 of 43 | 86 | NCT03201458 | Trial comparisons |
| Arm A (Atezolizumab) vs Arm B (Atezolizumab, Cobimetinib): serious adverse events | 32 of 43 | 31 of 43 | 86 | NCT03201458 | Trial comparisons |
| Infigratinib (BGJ398) 125 mg vs Gemcitabine + Cisplatin: Number of Participants With Serious Adverse Events (SAEs) | 10 of 29 | 0 of 17 | 46 | NCT03773302 | Trial comparisons |
| Infigratinib (BGJ398) 125 mg vs Gemcitabine + Cisplatin: Number of Participants With Adverse Events (AEs) | 29 of 29 | 17 of 17 | 46 | NCT03773302 | Trial comparisons |
| Infigratinib (BGJ398) 125 mg vs Gemcitabine + Cisplatin: deaths from any cause | 0 of 29 | 0 of 17 | 46 | NCT03773302 | Trial comparisons |
| Infigratinib (BGJ398) 125 mg vs Gemcitabine + Cisplatin: serious adverse events | 10 of 29 | 0 of 17 | 46 | NCT03773302 | Trial comparisons |
| Stratum: 1 Prior Regimen vs Stratum 2: No Prior Therapy: serious adverse events | 4 of 18 | 2 of 26 | 44 | NCT00338988 | Trial comparisons |
| Arm A - Cholangiocarcinoma vs ARM B - Pancreatic Cancer: Number of Patients Experiencing a Grade 3 or Above Treatment-related Adverse Event (AE) | 5 of 13 | 19 of 30 | 43 | NCT03250273 | Trial comparisons |
| Arm A - Cholangiocarcinoma vs ARM B - Pancreatic Cancer: deaths from any cause | 0 of 13 | 1 of 30 | 43 | NCT03250273 | Trial comparisons |
| Arm A - Cholangiocarcinoma vs ARM B - Pancreatic Cancer: serious adverse events | 4 of 13 | 3 of 30 | 43 | NCT03250273 | Trial comparisons |
| Arm A - Cholangiocarcinoma vs ARM B - Pancreatic Cancer: Objective Response Rate (ORR) Using Response Evaluation Criteria for Solid Tumors (RECIST 1.1) | 0 of 13 | 3 of 27 | 40 | NCT03250273 | Trial comparisons |
| PCI Treatment in Conjunction With Standard of Care (SoC) vs Standard of Care (SoC): Overall Survival (OS) | 12 of 19 | 13 of 15 | 34 | NCT04099888 | Trial comparisons |
| PCI Treatment in Conjunction With Standard of Care (SoC) vs Standard of Care (SoC): Adverse Events (AEs)/Serious Adverse Events (SAEs) | 12 of 18 | 8 of 16 | 34 | NCT04099888 | Trial comparisons |
| PCI Treatment in Conjunction With Standard of Care (SoC) vs Standard of Care (SoC): Loco-regional Tumour-related Events and Biliary Complications | 12 of 18 | 8 of 16 | 34 | NCT04099888 | Trial comparisons |
| PCI Treatment in Conjunction With Standard of Care (SoC) vs Standard of Care (SoC): deaths from any cause | 7 of 19 | 2 of 15 | 34 | NCT04099888 | Trial comparisons |
| PCI Treatment in Conjunction With Standard of Care (SoC) vs Standard of Care (SoC): Objective Response Rate (ORR) | 3 of 19 | 3 of 15 | 34 | NCT04099888 | Trial comparisons |
| PCI Treatment in Conjunction With Standard of Care (SoC) vs Standard of Care (SoC): serious adverse events | 12 of 18 | 8 of 16 | 34 | NCT04099888 | Trial comparisons |
| Photodynamic Therapy-Photofrin Plus SMC vs Standard Medical Care (SMC): deaths from any cause | 1 of 15 | 0 of 13 | 28 | NCT02082522 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0019087/comparisons